BEAM Beam Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BEAM

Price (delayed)

$30.39

Market cap

$2.2B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.13

Enterprise value

$2.14B

Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a ...

Highlights
The EPS is up by 28% year-on-year and by 8% since the previous quarter
The net income has increased by 22% year-on-year and by 8% since the previous quarter
BEAM's gross profit is down by 34% since the previous quarter but it is up by 18% year-on-year
Beam Therapeutics's revenue has decreased by 34% from the previous quarter but it has increased by 18% YoY
The debt has grown by 23% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://beamtx.com
Peers: OVID

Key stats

What are the main financial stats of BEAM
Market
Shares outstanding
72.4M
Market cap
$2.2B
Enterprise value
$2.14B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.92
Price to sales (P/S)
34.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
35.07
Earnings
Revenue
$60.92M
EBIT
-$285.68M
EBITDA
-$271.53M
Free cash flow
-$26.42M
Per share
EPS
-$4.13
Free cash flow per share
-$0.38
Book value per share
$10.41
Revenue per share
$0.87
TBVPS
$19.16
Balance sheet
Total assets
$1.34B
Total liabilities
$608.24M
Debt
$182.01M
Equity
$733.47M
Working capital
$869.3M
Liquidity
Debt to equity
0.25
Current ratio
4.89
Quick ratio
4.88
Net debt/EBITDA
0.23
Margins
EBITDA margin
-445.7%
Gross margin
100%
Net margin
-474.5%
Operating margin
-555.6%
Efficiency
Return on assets
-20.8%
Return on equity
-37.6%
Return on invested capital
-26.2%
Return on capital employed
-25.5%
Return on sales
-468.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BEAM stock price

How has the Beam Therapeutics stock price performed over time
Intraday
0.16%
1 week
-8.52%
1 month
-21.92%
1 year
-48.21%
YTD
-22.3%
QTD
-22.3%

Financial performance

How have Beam Therapeutics's revenue and profit performed over time
Revenue
$60.92M
Gross profit
$60.92M
Operating income
-$338.48M
Net income
-$289.09M
Gross margin
100%
Net margin
-474.5%
Beam Therapeutics's operating margin has shrunk by 63% QoQ but it has increased by 27% YoY
The net margin has contracted by 38% from the previous quarter but it has grown by 34% YoY
BEAM's gross profit is down by 34% since the previous quarter but it is up by 18% year-on-year
Beam Therapeutics's revenue has decreased by 34% from the previous quarter but it has increased by 18% YoY

Growth

What is Beam Therapeutics's growth rate over time

Valuation

What is Beam Therapeutics stock price valuation
P/E
N/A
P/B
2.92
P/S
34.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
35.07
The EPS is up by 28% year-on-year and by 8% since the previous quarter
The price to book (P/B) is 30% lower than the last 4 quarters average of 4.2
BEAM's equity is down by 11% year-on-year but it is up by 2.7% since the previous quarter
Beam Therapeutics's revenue has decreased by 34% from the previous quarter but it has increased by 18% YoY
BEAM's price to sales (P/S) is 23% lower than its last 4 quarters average of 45.5

Efficiency

How efficient is Beam Therapeutics business performance
BEAM's ROIC has soared by 52% YoY and by 14% QoQ
The company's return on assets rose by 41% YoY and by 6% QoQ
The return on sales has declined by 38% since the previous quarter but it is up by 34% year-on-year
The ROE has increased by 33% YoY and by 6% QoQ

Dividends

What is BEAM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BEAM.

Financial health

How did Beam Therapeutics financials performed over time
The total assets is 121% more than the total liabilities
BEAM's quick ratio is down by 19% year-on-year but it is up by 5% since the previous quarter
BEAM's current ratio is down by 18% YoY but it is up by 5% QoQ
The debt is 75% less than the equity
The company's debt to equity rose by 39% YoY
The debt has grown by 23% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.